Tet2介导的克隆性造血通过IL-1β/NLRP3炎症小体机制加速心力衰竭
本研究在小鼠压力负荷和慢性缺血两种心衰模型中,采用Tet2缺陷细胞竞争性骨髓移植或髓系特异性Tet2敲除模拟克隆性造血。结果显示造血或髓系Tet2缺陷加重心脏重构和功能障碍,伴IL-1β表达升高;选择性NLRP3炎症小体抑制剂可保护心衰发生并消除Tet2缺陷与野生型小鼠的心脏参数差异。
要点
- 造血细胞Tet2缺陷加重小鼠心衰模型的心脏重构和功能障碍。
- Tet2缺陷伴随IL-1β表达升高,NLRP3抑制剂可消除其与野生型的心脏差异。
- TET2介导的克隆性造血个体可能心衰风险更高,或对IL-1β-NLRP3抑制反应更好。
核心结论
- 造血细胞Tet2缺陷通过升高IL-1β信号与小鼠心衰模型更严重的心脏功能障碍相关。
- TET2介导的克隆性造血个体可能心衰风险更高,且可能对IL-1β-NLRP3炎症小体抑制反应更好。
研究设计与样本
- 研究采用小鼠压力负荷(横向主动脉缩窄)和慢性缺血(永久结扎左前降支动脉)两种心衰模型。
- 使用Tet2缺陷细胞竞争性骨髓移植模拟TET2突变驱动的克隆性造血。
- 另采用LysM启动子驱动的Cre重组酶在髓系细胞中特异性敲除Tet2。
主要发现
- 在两种实验性心衰模型中,造血或髓系Tet2缺陷均加重心脏重构和功能,并伴随白细胞介素-1β(IL-1β)表达升高。
- 选择性NLRP3炎症小体抑制剂治疗可防止心衰发生,并消除Tet2缺陷与野生型小鼠之间的心脏参数差异。
临床怎么用
- 对于存在TET2介导的克隆性造血个体,应关注其心衰风险。
- IL-1β-NLRP3炎症小体抑制可能是该类人群心衰的潜在治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent studies have shown that hematopoietic stem cells can undergo clonal expansion secondary to somatic mutations in leukemia-related genes, thus leading to an age-dependent accumulation of mutant leukocytes in the blood. This somatic mutation-related clonal hematopoiesis is common in healthy older individuals, but it has been associated with an increased incidence of future cardiovascular disease. The epigenetic regulator TET2 is frequently mutated in blood cells of individuals exhibiting clonal hematopoiesis. OBJECTIVES: This study investigated whether Tet2 mutations within hematopoietic cells can contribute to heart failure in 2 models of cardiac injury. METHODS: Heart failure was induced in mice by pressure overload, achieved by transverse aortic constriction or chronic ischemia induced by the permanent ligation of the left anterior descending artery. Competitive bone marrow transplantation strategies with Tet2-deficient cells were used to mimic TET2 mutation-driven clonal hematopoiesis. Alternatively, Tet2 was specifically ablated in myeloid cells using Cre recombinase expressed from the LysM promoter. RESULTS: In both experimental heart failure models, hematopoietic or myeloid Tet2 deficiency worsened cardiac remodeling and function, in parallel with increased interleukin-1beta (IL-1β) expression. Treatment with a selective NLRP3 inflammasome inhibitor protected against the development of heart failure and eliminated the differences in cardiac parameters between Tet2-deficient and wild-type mice. CONCLUSIONS: Tet2 deficiency in hematopoietic cells is associated with greater cardiac dysfunction in murine models of heart failure as a result of elevated IL-1β signaling. These data suggest that individuals with TET2-mediated clonal hematopoiesis may be at greater risk of developing heart failure and respond better to IL-1β-NLRP3 inflammasome inhibition.
引用
- Sano S, Oshima K, Wang Y, et al. Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome. J Am Coll Cardiol. 2018. PMID: 29471939. doi:10.1016/j.jacc.2017.12.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。